Shots: Bio-Thera to receive an up front, milestones along with royalties on product sales & will be responsible for the development, manufacturing, supply of BAT1706 Sandoz to get rights for the commercialization of the therapy upon approval in the US, EU, Canada, and other countries. Bio-Thera’s BAT1706 has completed extensive biosimilar studies, including a global […]Read More
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of August, Samsung Bioepis’ Byooviz (biosimilar, ranibizumab) received EC’s […]Read More
Shots: The PATRO Children, post marketing surveillance study evaluates biosimilar rhGH (Omnitrope) vs reference rhGH (Genotropin) in 348 children with TS at 130 centers across EU. In this study, 81.6% were rhGH naïve, and 90.2% were prepubertal The results demonstrated that the therapy was safe & effective in real-life clinical practice, was generally well tolerated […]Read More
The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for Molnupiravir to treat COVID-19 The big acquisition took place during the quarter including Microsoft acquired Nuance for ~$19.7B, MorphoSys acquired Constellation for ~$1.7B Our team […]Read More
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, Samsung initiated patient enrollment in the P-III […]Read More
Shots: The US Supreme Court has denied Sandoz’ petition to review Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi (etanercept-szzs) for the reference product, Enbrel (etanercept) The company was unable to launch the product in the US due to patent litigation. The affordable biosimilar will not be available in the US till 2029 […]Read More
Shots: The company expands its portfolio with the marketing of the 6th biosimilars in Canada. Inclunox and Inclunox HP (enoxaparin sodium solution for injection) is indicated for use in 6 indications of the reference Lovenox and Lovenox HP in oncology, immunology, and endocrinology Sandoz Canada has completed the pCPA negotiations for Inclunox and Inclunox HP, […]Read More
AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer Published: May 7, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab, Tremelimumab, P-III, POSEIDON Study, Stage IV Non-Small Cell Lung Cancer Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + […]Read More
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Biocon and Viatris received EC’s approval for […]Read More
Shots: The company starts enrolling patients in the P-III MYLIGHT study to evaluate the safety and efficacy of biosimilar aflibercept vs Eylea in patients with nAMD for 48wks. The study is expected to enroll 460 patients across 20 countries The study is a part of a biosimilar development program that includes analytical, pre/ clinical data. […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
